A Phase 3 Randomized Withdrawal, Double-blind, Placebo-controlled, Multi-center Study Investigating The Efficacy And Safety Of Pf-04965842 In Subjects Aged 12 Years And Over, With Moderate To Severe Atopic Dermatitis With The Option Of Rescue Treatment In Flaring Subjects
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 16 Aug 2018 Planned End Date changed from 2 Jul 2020 to 3 Jul 2020.
- 16 Aug 2018 Planned primary completion date changed from 2 Jul 2020 to 3 Jul 2020.
- 11 Jul 2018 New trial record